Patents by Inventor Nilendu Panda
Nilendu Panda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11390612Abstract: The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.Type: GrantFiled: October 1, 2020Date of Patent: July 19, 2022Assignee: Fresenius Kabi Oncology Ltd.Inventors: Walter Cabri, Saswata Lahiri, Bhuwan Bhaskar Mishra, Abul Azim, Nilendu Panda, Poli Reddy Bhavanam, Krishanu Ray, Nikunj Kachhadia, Kumber Singh
-
Publication number: 20210024506Abstract: The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.Type: ApplicationFiled: October 1, 2020Publication date: January 28, 2021Applicant: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Walter CABRI, Saswata LAHIRI, Bhuwan Bhaskar MISHRA, Abul AZIM, Nilendu PANDA, Poli Reddy BHAVANAM, Krishanu RAY, Nikunj KACHHADIA, Kumber SINGH
-
Patent number: 10800763Abstract: The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.Type: GrantFiled: June 10, 2016Date of Patent: October 13, 2020Assignee: Fresenius Kabi Oncology Ltd.Inventors: Walter Cabri, Saswata Lahiri, Bhuwan Bhaskar Mishra, Abul Azim, Nilendu Panda, Poli Reddy Bhavanam, Krishanu Ray, Nikunj Kachhadia, Kumber Singh
-
Publication number: 20180312494Abstract: The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.Type: ApplicationFiled: June 10, 2016Publication date: November 1, 2018Applicant: FRESENIUS KABI ONCOLOGY LTD.Inventors: Walter CABRI, Saswata LAHIRI, Bhuwan Bhaskar MISHRA, Abul AZIM, Nilendu PANDA, Poli Reddy BHAVANAM, Krishanu RAY, Nikunj KACHHADIA, Kumber SINGH
-
Patent number: 9440979Abstract: An improved process for the preparation of Pralatrexate which is less hazardous. The invention further relates to novel intermediates and process thereof useful for the preparation of Pralatrexate. The present invention also relates to a substantially pure Pralatrexate and a process for obtaining the same in high yield.Type: GrantFiled: July 18, 2013Date of Patent: September 13, 2016Assignee: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Saswata Lahiri, Nitin Gupta, Hemant Kumar Singh, Nilendu Panda, Vishal Handa, Azim Abul, Chandan Kumar Gupta, Sunil Sanghani, Ghanashyam Madhukar Sonavane
-
Patent number: 9199953Abstract: An amorphous form of cabazitaxel is disclosed. It is preferably characterized by an X-ray powder diffraction (XRD) pattern as depicted in FIG. 1. It is prepared by (a) preparing a solution of cabazitaxel in a suitable solvent and mixture thereof; and (b) recovering the amorphous forms of cabazitaxel from the solution by removal of the solvent.Type: GrantFiled: October 30, 2012Date of Patent: December 1, 2015Assignee: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Saswata Lahiri, Bhuwan Bhaskar Mishra, Vijay Ojha, Nilendu Panda, Sonu Prasad Shukla
-
Publication number: 20150183789Abstract: An improved process for the preparation of Pralatrexate which is less hazardous. The invention further relates to novel intermediates and process thereof useful for the preparation of Pralatrexate. The present invention also relates to a substantially pure Pralatrexate and a process for obtaining the same in high yield.Type: ApplicationFiled: July 18, 2013Publication date: July 2, 2015Applicant: Fresenius Kabi Oncology LimitedInventors: Saswata Lahiri, Nitin Gupta, Hemant Kumar Singh, Nilendu Panda, Vishal Handa, Azim Abul, Chandan Kumar Gupta, Sunil Sanghani, Ghanashyam Madhukar Sonavane
-
Patent number: 9000193Abstract: The present invention discloses a process for the preparation of 4-acetoxy-2?-benzoyloxy-5?,20-epoxy-1-hydroxy-7?,10?-dimethoxy-9-oxotax-11-en-13?-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate Cabazitaxel (I).Type: GrantFiled: November 5, 2014Date of Patent: April 7, 2015Assignee: Fresenius Kabi Oncology LimitedInventors: Saswata Lahiri, Nitin Gupta, Abul Azim, Nilendu Panda, Bhuwan Bhaskar Mishra, Sunil Sanghani
-
Publication number: 20150057454Abstract: The present invention discloses a process for the preparation of 4-acetoxy-2?-benzoyloxy-5?,20-epoxy-1-hydroxy-7?,10?-dimethoxy-9-oxotax-11-en-13?-yl(2 R,35)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate Cabazitaxel (I).Type: ApplicationFiled: November 5, 2014Publication date: February 26, 2015Inventors: Saswata Lahiri, Nitin Gupta, Abul Azim, Nilendu Panda, Bhuwan Bhaskar Mishra, Sunil Sanghani
-
Patent number: 8901322Abstract: The present invention provides Crystalline Forms of 4-acetoxy-2?-benzoyloxy-5?-20-epoxy-1-hydroxy-7?,10?-dimethoxy-9-oxotax-11-en-13?-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate, i.e Cabazitaxel. The present invention also discloses methods for the preparation of Crystalline Forms of Cabazitaxel and pharmaceutical compositions thereof.Type: GrantFiled: November 21, 2012Date of Patent: December 2, 2014Assignee: Fresenius Kabi Oncology LimitedInventors: Saswata Lahiri, Rajesh Srivastava, Bhuwan Bhaskar Mishra, Shatrughan Sharma, Vijay Ojha, Nilendu Panda, Sandeep Kumar, Sonu Prasad
-
Patent number: 8901327Abstract: The present invention discloses a process for the preparation of 4-acetoxy-2?-benzoyloxy-5?,20-epoxy-1-hydroxy-7?,10?-dimethoxy-9-oxotax-11-en-13?-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate Cabazitaxel (I).Type: GrantFiled: September 24, 2012Date of Patent: December 2, 2014Assignee: Fresenius Kabi Oncology LimitedInventors: Saswata Lahiri, Nitin Gupta, Abul Azim, Nilendu Panda, Bhuwan Bhaskar Mishra, Sunil Sanghani
-
Publication number: 20140058119Abstract: The present invention discloses a process for the preparation of 4-acetoxy-2?-benzoyloxy-5?,20-epoxy-1-hydroxy-7?,10?-dimethoxy-9-oxotax-11-en-13?-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate Cabazitaxel (I).Type: ApplicationFiled: September 24, 2012Publication date: February 27, 2014Applicant: FRESENIUS KABI ONCOLOGY LIMITEDInventors: Saswata LAHIRI, Nitin GUPTA, Abul AZIM, Nilendu PANDA, Bhuwan Bhaskar MISHRA, Sunil SANGHANI
-
Patent number: 8383690Abstract: The present invention deals with the pharmaceutical composition comprising the therapeutically effective amount of a compound oenothein C obtained from the bioactive fraction of plant Woodfordia fruticosa optionally along with one or more pharmaceutically acceptable carriers, additives, lubricants and diluents. Further it also provides a method of treating peptic ulcer diseases in a subject using the said pharmaceutical composition. It also relates to the use of the compound oenothein C in the treatment of peptic ulcer related diseases and a process for the isolation of the said compound.Type: GrantFiled: May 4, 2011Date of Patent: February 26, 2013Assignee: Council of Scientific and Industrial ResearchInventors: Sukdeb Banerjee, Pratap K. Das, Suchandra Goswami, Annalakshmi Chinniah, Nilendu Panda, Niranjan Prasad Sahu, Basudeb Achari
-
Publication number: 20110207682Abstract: The present invention deals with the pharmaceutical composition comprising the therapeutically effective amount of a compound oenothein C obtained from the bioactive fraction of plant Woodfordia fruticosa optionally along with one or more pharmaceutically acceptable carriers, additives, lubricants and diluents. Further it also provides a method of treating peptic ulcer diseases in a subject using the said pharmaceutical composition. It also relates to the use of the compound oenothein C in the treatment of peptic ulcer related diseases and a process for the isolation of the said compound.Type: ApplicationFiled: May 4, 2011Publication date: August 25, 2011Inventors: Sukdeb Banerjee, Pratap K. Das, Suchandra Goswami, Annalakshmi Chinniah, Nilendu Panda, Niranjan P. Sahu, Basudeb Achari
-
Publication number: 20080274985Abstract: The present invention deals with the pharmaceutical composition comprising the therapeutically effective amount of a compound oenothein C obtained from the bioactive fraction of plant Woodfordia fruticosa optionally along with one or more pharmaceutically acceptable carriers, additives, lubricants and diluents. Further it also provides a method of treating peptic ulcer diseases in a subject using the said pharmaceutical composition. It also relates to the use of the compound oenothein C in the treatment of peptic ulcer related diseases and a process for the isolation of the said compound.Type: ApplicationFiled: February 12, 2007Publication date: November 6, 2008Inventors: Sukdeb Banerjee, Pratap K. Das, Suchandra Goswami, Annalakshmi Chinniah, Nilendu Panda, Niranjan P. Sahu, Basudeb Achari